Harfst & Associates’s AstraZeneca AZN Stock Holding History

Harfst & Associates’s Portfolio AZN Stock Details AZN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q3	–	Sell	-11,900	Closed	-$675K	–	77
2016 Q2	$675K	Buy	+11,900	New	+$691K	0.27%	65
2016 Q1	–	Sell	-11,980	Closed	-$813K	–	83
2015 Q4	$813K	Buy	11,980 +30	+0.3%	+$1.97K	0.33%	63
2015 Q3	$760K	Buy	11,950 +10,578	+771%	+$696K	0.33%	64
2015 Q2	$87K	Buy	+1,372	New	+$93.9K	0.05%	134

Other funds holding AZN

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

BIM

BlackRock Investment Management Wilmington, Delaware $86.4B AUM 16.83% 1-Year Est. Return

EIP

Epoch Investment Partners New York $17.6B AUM 34.17% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return

Harfst & Associates's AZN Position: Q3 2016 in Review

Harfst & Associates sold out of AstraZeneca (AZN) in Q3 2016, closing a stake of 11,900 shares — an estimated $675K sold.

Harfst & Associates first reported a position in AZN in Q2 2015 and held it in 4 quarters. The position peaked at $813K in Q4 2015. 451 funds tracked by Wall St. Rank hold AZN as of Q3 2016.

Harfst & Associates reported no remaining AstraZeneca position as of Q3 2016 after selling out during the quarter.
Harfst & Associates sold 11,900 AstraZeneca shares in Q3 2016, an estimated $675K.
Harfst & Associates first reported a position in AstraZeneca in Q2 2015 and held it in 4 quarters.
Harfst & Associates's AstraZeneca position peaked at $813K in Q4 2015.
451 funds tracked by Wall St. Rank held AstraZeneca as of Q3 2016.

Based on Harfst & Associates's 13F filing for Q3 2016, filed 14 Nov 2016.